VanEck Associates’s Adaptive Biotechnologies ADPT Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$257K Buy
+8,886
New +$218K ﹤0.01% 1300
2023
Q4
– Sell
-1,787
Closed -$10K – 1392
2023
Q3
$10K Hold
1,787
– – ﹤0.01% 1354
2023
Q2
$12K Hold
1,787
– – ﹤0.01% 1359
2023
Q1
$16K Sell
1,787
-6
-0.3% -$53 ﹤0.01% 1359
2022
Q4
$14K Buy
1,793
+309
+21% +$2.4K ﹤0.01% 1370
2022
Q3
$11K Buy
+1,484
New +$14K ﹤0.01% 1336

Other funds holding ADPT

VanEck Associates's ADPT Position: Q3 2026 in Review

VanEck Associates opened a new position in Adaptive Biotechnologies (ADPT) in Q3 2026: 8,886 shares worth $257K. The stake represents ﹤0.01% of the portfolio and ranks #1300 among its holdings. This is a return to the name: VanEck Associates previously reported a position in ADPT as recently as Q3 2023.

VanEck Associates first reported a position in ADPT in Q3 2022 and has held it in 6 quarters since. 332 funds tracked by Wall St. Rank hold ADPT as of Q3 2026.

  • VanEck Associates held 8,886 shares of Adaptive Biotechnologies worth $257K as of Q3 2026.
  • Adaptive Biotechnologies was a new VanEck Associates position in Q3 2026.
  • Adaptive Biotechnologies made up ﹤0.01% of VanEck Associates's portfolio in Q3 2026, its #1300 holding.
  • VanEck Associates first reported a position in Adaptive Biotechnologies in Q3 2022 and has held it in 6 quarters since.
  • 332 funds tracked by Wall St. Rank held Adaptive Biotechnologies as of Q3 2026.

Based on VanEck Associates's 13F filing for Q3 2026, filed 13 Nov 2026.